Opko Health (NASDAQ:OPK) announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.08), Briefing.com reports. Opko Health had a negative return on equity of 9.86% and a negative net margin of 19.92%. The company had revenue of $222.50 million for the quarter, compared to analyst estimates of $241.27 million. During the same period in the previous year, the firm posted ($0.08) earnings per share. The firm’s quarterly revenue was down 12.7% compared to the same quarter last year.
NASDAQ OPK traded down $0.08 on Friday, reaching $1.78. The company had a trading volume of 1,845,739 shares, compared to its average volume of 5,406,836. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.99 and a current ratio of 1.10. The company has a market cap of $1.11 billion, a P/E ratio of -7.10 and a beta of 1.81. Opko Health has a 12 month low of $1.82 and a 12 month high of $6.40.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research cut shares of Opko Health from a “buy” rating to a “hold” rating in a report on Monday, February 4th. Barrington Research reissued a “buy” rating and set a $5.00 target price on shares of Opko Health in a report on Thursday, February 28th. Finally, ValuEngine cut Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Opko Health has a consensus rating of “Buy” and a consensus target price of $9.25.
A number of institutional investors have recently added to or reduced their stakes in OPK. BlackRock Inc. lifted its position in shares of Opko Health by 1.4% in the 4th quarter. BlackRock Inc. now owns 30,276,662 shares of the biotechnology company’s stock worth $91,133,000 after purchasing an additional 408,951 shares during the period. Vanguard Group Inc. boosted its holdings in Opko Health by 2.1% during the third quarter. Vanguard Group Inc. now owns 29,660,750 shares of the biotechnology company’s stock worth $102,626,000 after buying an additional 614,442 shares in the last quarter. Vanguard Group Inc boosted its holdings in Opko Health by 2.1% during the third quarter. Vanguard Group Inc now owns 29,660,750 shares of the biotechnology company’s stock worth $102,626,000 after buying an additional 614,442 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Opko Health by 11.0% during the first quarter. Geode Capital Management LLC now owns 4,527,632 shares of the biotechnology company’s stock worth $11,817,000 after buying an additional 449,235 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Opko Health by 25.3% during the third quarter. Dimensional Fund Advisors LP now owns 4,440,784 shares of the biotechnology company’s stock worth $15,363,000 after buying an additional 897,406 shares in the last quarter. 25.36% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was first posted by Rockland Register and is the property of of Rockland Register. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://rocklandregister.com/2019/05/31/opko-health-opk-announces-earnings-results-misses-expectations-by-0-08-eps.html.
About Opko Health
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.
Read More: Trading signals using Bollinger bands
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.